AbbVie Inc. said that 75,743,313 common shares were tendered to its tender offer, which expired May 29.
The North Chicago, Ill.-based pharmaceutical giant said it expects to buy back 71.4 million common shares, or about 4.5% of its outstanding stock, at $105 apiece for a cost of about $7.5 billion, excluding fees and expenses.
